Cancer Care


A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Principal Investigator (?)
Study Number
This randomized phase II trial studies low-dose or high-dose lenalidomide to see how well it
works in treating younger patients with recurrent, refractory, or progressive juvenile
pilocytic astrocytomas or optic nerve pathway gliomas. Lenalidomide may stop the growth of
tumor cells by blocking blood flow to the tumor.
Phase (?)
Phase II
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.